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Abstract: Efficient delivery of genetic material into cells is a critical process to translate gene therapy
into clinical practice. In this sense, the increased knowledge acquired during past years in the
molecular biology and nanotechnology fields has contributed to the development of different kinds
of non-viral vector systems as a promising alternative to virus-based gene delivery counterparts.
Consequently, the development of non-viral vectors has gained attention, and nowadays, gene
delivery mediated by these systems is considered as the cornerstone of modern gene therapy due to
relevant advantages such as low toxicity, poor immunogenicity and high packing capacity. However,
despite these relevant advantages, non-viral vectors have been poorly translated into clinical success.
This review addresses some critical issues that need to be considered for clinical practice application
of non-viral vectors in mainstream medicine, such as efficiency, biocompatibility, long-lasting effect,
route of administration, design of experimental condition or commercialization process. In addition,
potential strategies for overcoming main hurdles are also addressed. Overall, this review aims to
raise awareness among the scientific community and help researchers gain knowledge in the design
of safe and efficient non-viral gene delivery systems for clinical applications to progress in the gene
therapy field.
Keywords: non-viral vectors; gene therapy; nanotechnology; gene delivery; clinical translation
1. Introduction
The main concept of gene therapy is quite simple and overall relies on the delivery
of exogenous genetic material into target cells to modulate the expression of an altered
genome. Basically, three different approaches can be identified (Figure 1). In the case of gene
addition therapy, a “healthy” copy of the gene is administered to recover the functionality
of the affected cells. This strategy can be suitable to face diseases caused by mutations
with loss of function [1]. For instance, the autosomal recessive cystic fibrosis disease
caused by a deletion of the phenylalanine at the position 508 of the CFTR (cystic fibrosis
transmembrane conductance regulator) protein [2]. However, in the case of a mutation
that overexpresses genes, the aim is to administer an inhibitory sequence to knock out the
expression of the mutated gene [3]. This strategy is referred to as gene inhibition therapy and
can be applied, for instance, to face autosomal dominant retinitis pigmentosa secondary to
specific mutations in the pre-mRNA splicing-factor gene PRPF31 [4]. The third approach,
named as genome editing, incorporates specific genome editing tools to repair mutations in
the genome with gain or loss of function [5]. This strategy has been successfully used in
combination with iPSC technologies to combat human β-thalassemia disease in mice [6].
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The main characteristics and composition of the genetic cargo strongly depend on 
the gene therapy approach used (Table 1). For instance, in the case of the gene addition 
approach, which is classically used to face genetic disorders that follow an autosomal 
recessive inheritance pattern, the most common polynucleotide used is referred to as 
plasmid (pDNA). Such a plasmid is a circular and double-stranded DNA construct, 
typically between 1.5 and 20 kbs, that drives the transient transgene expression in the 
nucleus of target cells, encoding the protein of interest [7]. Typically, a transfection 
mediated by conventional pDNAs is moderated and only active during 1–2 months. 
However, smaller versions of a conventional pDNA, known as minicircle DNA (mcDNA, 
2–6 kbs) or micro-intronic plasmid (2–4 kbs), can improve transgene expression by 10- to 
100-fold and prolong the effect for some years [8,9]. Another commonly used 
polynucleotide in the gene addition approach is the single strand messenger RNA (mRNA). 
Nowadays, this strategy holds great promise, especially in the vaccine research area, since 
two vaccines produced by Moderna and Pfizer/BioNTech companies have been recently 
approved by the European Medicines Agency (EMA) to fight against the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting 
coronavirus disease (Covid-19). As in the case of pDNA, the effect mediated by mRNAs 
is also transient and the stability in plasma is even lower, around 1 h. The less tight 
conformation of RNA, which allows an easier access of the degradative enzymes, and also 
the presence of hydroxyl groups in the main structure, which enhances hydrolyzation of 
RNAs [10,11], significantly contribute to decrease the stability. However, the main 
advantages of RNA-based gene therapy compared to pDNA include a safer profile, since 
it decreases the risk of mutagenesis and immunogenicity and a more efficient modulation 
of target gene expression because the place of action of this genetic cargo is in the 
cytoplasm [12]. Therefore, there is no need to get access into the nucleus of cells, which is 
classically considered as one of the main bottlenecks of plasmid-based expression systems 
[13].  
  
Figure 1. Brief schematic representation of three different genetic material-based approaches to face
human diseases. (a) Gene addition therapy. (b) Gene inhibition therapy. (c) Genome editing.
The ain characteristics and composition of the genetic cargo strongly depend on the
gene therapy approach used (Table 1). For instance, in the case of the gene addition approach,
which is classically used to face genetic disorders that follow an autosomal recessive
inheritance pattern, the most common polynucleotide used is referred to as plasmid
(pDNA). Such a plasmid is circular and double-stranded DNA construct, typically
between 1.5 and 20 kbs, that drives the transient transgene expr ssion in the ucleus
of target cells, encoding the protein of in rest [7]. Typically, a transfection mediated
by conventional pDNAs is moderated and only active during 1–2 mo ths. However,
smaller versions of a conventional pDNA, known as minicircle DNA (mcDNA, 2–6 kbs)
or micro-intronic plasmid (2–4 kbs), can improve transgene expr ssion by 10- to 100-fold
and prolong the effect for some years [8,9]. Another commonly used polynucleotide in
the gene add tion approach is the single strand m sseng r RNA (mRNA). Nowadays, this
strategy holds gre promise, especially in th va cine research area, since two v cc es
produced by Moderna and Pfizer/BioNTech companies have been rec ntly approved by the
European Medicines Agency (EMA) to fight against the severe acute respiratory syndrom
coron vi us 2 (SARS-CoV-2) i fection and the resulting coronavirus disease (COVID-19).
As in the case of pDNA, the effect mediated by mRNAs is also transient and the stability in
plasma is even lower, around 1 h. The less tight conformation of RNA, which allows an
easier access of the degradative enzymes, and also the presence of hydroxyl groups in the
main structure, which enhances hydrolyzation of RNAs [10,11], significantly contribute
to decrease the stability. However, the main advantages of RNA-based gene therapy
compared to pDNA include a safer profile, since it decreases the risk of mutagenesis and
immunogenicity and a more efficient modulation of target gene expression because the
place of action of this genetic cargo is in the cytoplasm [12]. Therefore, there is no need
to get access into the nucleus of cells, which is classically considered as one of the main
bottlenecks of plasmid-based expression systems [13].
In contrast to gene addition strategy, the inhibition approach can be used when the main
goal is to silence the expression of an altered gene that has a gain of function mutation. This
scenario is common in genetic disorders that follow an autosomal dominant inheritance
pattern [14]. In this case, the inhibitory sequence can also have a single strand RNA-based
structure, such as the microRNA (miRNA), or a double strand RNA structure, such as
the small interfering RNA (siRNA). Typically, these structures inhibit the translation of
mRNA in the RNA-induced silencing complex (RISC) of the cytoplasm in a transitory
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way to avoid the expression of the target gene [15]. Interestingly, other synthetic and
smaller single strand RNA/DNA structures, known as antisense oligonucleotides (AON),
can also inhibit mRNA translation by a different mechanism of action. In this case, the
oligonucleotide sequence interferes with pre- and mRNA in the nucleus or cytoplasm
through a complementary hybridization mechanism that enhances specificity but with
lower knockdown efficiency [16].
Table 1. Scheme of essential characteristics and properties of main polynucleotides used in oligo-based gene therapeutics
and gene therapy.
Mechanism
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transitory way to avoid the expression of the target gene [15]. Interestingly, other synthetic 
and smaller single strand RNA/DNA structures, known as antisense oligonucleotides 
(AON), can also inhibit mRNA translation by a different mechanism of action. In this case, 
the oligonucleotide sequence interferes with pre- and mRNA in the nucleus or cytoplasm 
through a complementary hybridization mechanism that enhances specificity but with 
lower knockdown efficiency [16].  
Apart from gene addition and gene inhibition strategies, another approach consists of 
the permanent correction of the mutated gene with the use of specific genome editing 
tools such as those developed by the game changer CRISPR/Cas9 technology [17]. In this 
case, once the mutated gene is identified, different RNA guides (gRNA), which recognize 
20 nucleotides of the mutated allele, can be designed and synthetized to be delivered 
alongside the Cas9 protein, which will cut the genome 3 nucleotides to the left side in the 
5′-3′ direction of the protospacer adjacent motif (PAM) region. In this scenario, a single 
strand DNA sequence with the corrected mutation, typically 100 nucleotides long, can be 
supplied as a donor template to be incorporated in the cell genome by the homologous 
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goal is to silence the expression of an altered gene that has a gain of function mutation. 
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Apa t from gene addition and gene inhibition strategi s, an ther pproach consists of
the permanent correction of the mutated gen with the use of specific genome editing
tools such as those devel p d by the ame hanger CRISPR/Cas9 tech ology [17]. I t is
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5′-3′ direction of the protospac r adjacent motif (PAM) region. In this scenario, a single
strand DNA sequence with the corrected mutation, typically 100 nucleotides long, can be
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recombination mecha ism [18]. Such CRISPR/C s9 editing tools can be delivered in
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extracellular and intracellular barriers to reach the pl ce of actio . In the case of in vitro
conditions, which is th simplest scenar o, only intracellular barri rs need to b considered.
However, in the case of i vivo experimentation, the delivery process to the lace of action
can als be affected by a diti nal extracellular arriers, which tr ngly de ends on the
route f ad inistrati n and the organ to b treated [20]. To overcom su h biological
barriers, g e delivery systems are nec ssary, si c ge tic cargo by itself in most of
the c ses, is n ffective. Classicall , gen del v y yst ms are divid d i to viral and
non-viral vect rs. Vir l v ct rs are recogn ze by their high gene elivery efficiency. In fact,
Int. J. Mol. Sci. 2021, 22, 7545 4 of 23
viruses have evolved along many years to infect efficiently different kinds of cells with their
genetic cargo, and currently, such viruses can be easily modified in the laboratory to deliver
the genetic cargo of interest into target cells, reducing their pathogenic effect [21]. As a
result, most of the clinical trials, and the great majority of gene therapy drugs approved
for human use by regulatory agencies, are based on viral vectors. Some examples of mar-
keted gene therapy products that use viral vectors include Luxturna, Zolgensma, Oncorine
and Imlygic, to name just a few [22,23]. However, relevant concern still remains in the
research community related, over all, to their potential immunogenicity and oncogenic
capacity [24,25]. In addition, previously mentioned approved drugs are highly expensive,
mainly due to the intrinsic characteristics of biologic drugs [26]. Therefore, interest in
non-viral gene delivery systems has recently gained momentum. A brief schematic repre-
sentation of both physical and chemical methods for non-viral gene delivery is summarized
in Figure 2.
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Co pared to their viral counterparts, non-viral vectors show some appealing proper-
ties such as lower immunogenicity, safer profile and higher genetic cargo packing capacity.
In addition, non-viral vectors are cheaper and easier to manufacture and scale up [27]. Due
to these obvious advantages, the gene delivery mediated by non-viral vectors is nowadays
considered the cornerstone of modern gene therapy, especially for CRISPR/Cas9 deliv-
ery, where non-viral vectors predominate over viral vectors at the preclinical level [28].
In any case, although with few exceptions, this strategy has been poorly translated into
clinical success. However, some promising clinical trials based on gene therapy treatments,
summarized in Figure 3, are ongoing.
In this review, some critical issues in the way to clinic application of non-viral vectors
(Figure 4) and potential strategies to overcome such hurdles have been addressed. More
specifically, special attention has been paid to the gene delivery efficiency and biocompati-
bility of non-viral vectors. Additionally, the duration of the transgene expression, along
with the route of administration, the design of experimental conditions and some concerns
related to the commercialization process, has also been discussed.
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2. Gene Delivery Efficiency
A critical issue that hampers the regular application of non-viral vectors into regular
medical practice is their low gene delivery efficiency [29]. In this sense, viral systems
cle rly surpass non-viral counterparts, robab y due to their continuous evolution along
millions of years, which has allowed them to get bett r access into the genome of the target
cell, overcoming both extracellular and intracellular barriers [30]. Nowad y , most of the
commercially available gene therapy-oriented drugs use recombinant viruses modified
in the laboratory, such as retroviruses, lentiviruses, adenoviruses or adeno-associated
viruses to shuttle their genetic cargo. However, their overall safety concerns related to the
biological origin and the low genetic cargo packing capacity, along with the difficulties
associated to scaling up their production and high cost of development, have contributed
to exploring different gene delivery approaches based on the design of novel non-viral
vectors [31]. Research on this area has quickly captured the attention of the scientific
community, and, currently, this strategy represents a safer and more affordable alternative,
although the gene delivery efficiency of these systems needs to be improved to reach a
regular clinical practice.
Gene delivery efficiency of non-viral vectors is typically evaluated at a preclinical level
once such systems have shown appropriate physicochemical and biophysical properties,
for instance, in terms of particle size, superficial charge, polydispersity, morphology and
capacity to bind and protect genetic material to release it without suffering any degradation,
since all these parameters can affect the transfection process [32]. Initially, and as a proof
of concept, gene delivery capacity is evaluated in culture cells and, for that purpose, the
expression of different reporter plasmids that encode fluorescent proteins [33] or enzymes,
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such as luciferase [34] or galactosidase [35], is employed to be quantitatively evaluated by
different techniques. In this sense, it is worth mentioning that each reporter plasmid and
corresponding assays have different sensitivity and their own metrics [36]. For example,
the reporter plasmid that encodes green fluorescent protein is a good descriptor of the
transfection efficiency at a single cell’s level, since results are typically expressed as the
percentage of live cells that show green signal by flow cytometry [37]. However, luciferase
expression provides information related to the plasmid expression in a whole population
of cells, since the luminescence is normalized by the quantity of proteins in cell lysates.
When a therapeutic genetic material, instead of the reporter one, is used in in vitro
conditions, it is also important to consider, from a practical point of view, the transfection ef-
ficiency value required to reach a therapeutic effect, which highly depends on the particular
application and disease. For instance, in the case of cystic fibrosis, an autosomal recessive
disorder caused by the dysfunction of the CFTR gene, 28% of living human cystic fibrosis
airway epithelial cells (CuFi-1) were transfected with the pEGFP reporter plasmid, using a
lipid-based non-viral vector, named as N3 [38]. Such formulation reported a 5-fold increase
of CFTR protein expression in transfected versus non-transfected cells with the pGM169
therapeutic plasmid, which led to 1.5-fold increment of the chloride channel functionality,
exceeding the value required to get a therapeutic benefit (Figure 5).




Figure 5. Transfection efficiency and therapeutic effect. (a) Percentage of live transfected CuFi-1 cells with the pEGFP 
reporter plasmid. (b) General scheme of transfection process with pGM169 therapeutic plasmid. (c) CFTR/β-actin protein 
expression determined by Western blot. (d) CFTR chloride channel activity determined by SPQ analysis. Reproduced with 
permission of [38]. 
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accumulation of metabolites that come from the degradation of different compounds 
present in non-viral vector formulations can also induce an inflammatory process and, 
therefore, cause toxicity. Nevertheless, the cytotoxic effect does not only depend on the 
non-viral vector’s compounds. The genetic material that is aimed to be delivered can also 
be toxic, considering, for instance, the bacterial origin of many plasmids that can enhance 
the induction of undesired immune responses and the secretion of proinflammatory 
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developed to mitigate some disadvantages associated with the use of conventional 
plasmids [31]. Such mcDNAs contain a minimal expression cassette, where the bacterial 
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permission of [38].
Such in vitro studies are typically used as a screening methodology to select the non-
viral vector candidates that show better performance before conducting in vivo studies,
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in accordance with the principle of the three Rs (replacement, reduction and refinement
of animal labs). This sequential approach is aimed to reduce the number of animals used
in in vivo experiments. However, it should also be borne in mind that a direct correlation
between in vitro and in vivo results in terms of gene delivery efficiency does not always
exist, essentially because experimental conditions in each scenario are quite different [37].
As a consequence, some readjustments in terms of the composition of the formulation,
preparation methods, doses or volumes to be administered need to be performed to succeed
in in vivo experiments [39].
In any case, the transfection efficiency of non-viral vectors is highly related to their
cytotoxic effect, which is also a highly cell-dependent process [40]. Therefore, a suitable
balance between the transfection efficiency value required to obtain a therapeutic effect and
the cytotoxic effect needs to be acquired for each clinical application to enhance translation
of non-viral vectors to the regular medicine practice. Such a toxic effect of non-viral vectors
depends on many physicochemical parameters that affect the gene delivery process such as
particle size, morphology and zeta potential of complexes [41]. In addition, the elaboration
method, along with the intrinsic properties of the materials used to obtain the different
kinds of non-viral vectors, can impact on the final cytotoxic effect, depending, for instance,
on the degradation rate or the persistence along the time in organs and tissues [42]. It should
also be kept in mind that the persistence and accumulation of metabolites that come from
the degradation of different compounds present in non-viral vector formulations can also
induce an inflammatory process and, therefore, cause toxicity. Nevertheless, the cytotoxic
effect does not only depend on the non-viral vector’s compounds. The genetic material
that is aimed to be delivered can also be toxic, considering, for instance, the bacterial origin
of many plasmids that can enhance the induction of undesired immune responses and
the secretion of proinflammatory cytokines [43]. Interestingly, small plasmidic cassettes as
mcDNA have been recently developed to mitigate some disadvantages associated with the
use of conventional plasmids [31]. Such mcDNAs contain a minimal expression cassette,
where the bacterial backbone DNA has been eliminated, which reduces the unwanted
immunogenic responses and enhances the transfection efficiency due to the reduced size
of this CpG-free genetic material [8,44]. The cytotoxic effect of the non-viral vectors can
be qualitatively evaluated by different techniques based on microscopy analyses [45].
However, normally, quantitative analysis of toxicity is assessed by means of a broad
spectrum of cell viability/cytotoxicity colorimetric available kits, such as, for instance,
CCK8, MTT assay and Alamar BlueTM, or by mean of flow cytometer analysis [46–48].
In this sense, it is worth mentioning that many chemical compounds that are present in
non-viral vector formulations can interfere with the previously described colorimetric
assays, providing confusing results. In the case of flow cytometer analysis, fluorescent dyes
such as ethidium homodimer-1, propidium iodide or 7-Amino-actinomycin D (7-AAD) are
normally used to stain and analyze dead cells, which should be excluded from the final
transfection efficiency results [49].
To reduce the cytotoxic effect of non-viral vector formulations, many natural com-
pounds, such as cholesterol [50], lycopene [39] or squalene [33], can be incorporated into
lipid vesicles as “helper” components. In addition, some non-ionic surfactants, such as
polysorbate 80, can also reduce the toxic effect of cationic lipids [51]. Although the use of
cationic materials, such as the mentioned cationic lipids or polycationic polymers, facili-
tates the complexation with the negatively charged nucleic acids for gene delivery as well
as cellular internalization, an excess of positive charge can have detrimental effects on cell
viability. Hence, other strategies to avoid cationic vectors, and thus cytotoxicity, have been
developed for nucleic acid delivery [52]. In the case of polymeric-based non-viral vector
formulations, stimuli responsive polymers, also knowns as intelligent polymers, represent
an appealing approach to enhance not only biocompatibility of the formulation but also
the specificity and the duration of the gene expression [53]. These particular polymers
can modify their biological performance in response to small environmental changes of
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physicochemical parameters such as pH value, temperature or ionic strength to name just
some of the most relevant ones [54].
3. Duration of Gene Expression
Another main reason that limits the clinical application of non-viral vectors into reg-
ular medical practice is the loss of transgene expression over time in clinical trials. A
transgene expression can decrease with time because of many causes such as the inactiva-
tion of the genetic material by nucleases, the loss of activity by recombination processes,
the ineffective distribution into intracellular vesicles, or even the recognition and sub-
sequent silencing of foreign DNA by the host immune system [55]. In this sense, while
the retroviral and lentiviral vectors do integrate into the host cell genome, providing a
long-lasting effect [56,57], the main reason for adeno-associated viruses (AAV) vectors to
provide sustained transgene expression is not integration. AAV vectors barely integrate
into the genome unlike wild-type AAV. In contrast, an AAV vector genome persists in
the host cell nucleus as episomal concatemers that are highly resistant to nucleases. The
fact that AAV genomes are diluted over time as the cell undergoes repeated rounds of
replication, with the rate of transgene loss dependent on the turnover rate of the transduced
cell [58], is a proof of the occurrence. For instance, commercially available Luxturna drug
delivers by means of an AAV type 2 a healthy copy of the RPE65 gene into the subretinal
space of patients affected by retinitis pigmentosa and Leber congenital amaurosis. Despite
the high cost of the treatment, around $850,000, only one injection is required to complete
the treatment, due to the long-lasting effect obtained, in slow dividing cells of the retina.
This fact is particularly relevant in the case of invasive routes of administrations, such
as intravitreal, subretinal or administrations, into the cerebral cortex after craniotomy. In
this scenario, repeated administrations could increase the after-care cost due to additional
hospital visits [59], and, in many cases, jeopardize the acceptance of these aggressive gene
delivering routes because of the cumbersome approach and related side effects.
Most of the strategies that have been developed by the research community to enhance
the lasting effect of transgene expression are mainly focused on modifications of the genetic
material to be delivered rather than on modification on the components of the non-viral
vector formulation. For example, in the case of the gene addition approach, the previously
described mcDNA technology not only reduces the cytotoxic effect but also represents a
promising approach to prolong the therapeutic effect when this genetic cargo is combined
with non-viral vectors [8]. The lack of bacterial backbone sequences, along with the low
content of unmethylated CpG dinucleotides, reduces the activation of nuclear transgene
silencing mechanisms, which finally results in a sustained transgene expression effect
(Figure 6, [60]).
In addition, to prolong the effect, the transgenes of interest can be incorporated into
the host genome by means of viral integrase or site-specific recombinase enzymes, or
by the addition of transposable elements, such as transposons or “jumping” genes [55].
In any case, the translation into the clinic of these promising approaches to enhance the
transgene expression effect is clearly conditioned by relevant safety issues such as the pos-
sible induction of insertional mutagenesis in the host cells with permanent consequences.
Another approach that can be used to prolong the transgene expression effect consists
of the addition of viral DNA sequences that allow plasmid replication outside the chro-
mosomes. However, again, safety concerns can arise due to the viral DNA nature that
is associated with immune responses and the risk of oncogenesis. As a safer alternative
to the aforementioned viral sequences, mammalian scaffold/matrix attachment regions
(S/MARs) can also be incorporated into pDNA to enhance the episomal replication of
plasmids [61]. Episome sequences autonomously replicate plasmids that do not need to be
integrated into the host genome to express the transgene, which minimizes the mutagenesis
risk [62]. Episomal replicating plasmids are especially interesting to face tumor cells by
gene therapy, where a vertical transfer of the therapeutic plasmids is particularly relevant
in fast-dividing malignant cells [63]. Gene expression can also be prolonged by specific
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inhibition of gene silencing mechanisms of cells that hampers transgene expression [64].
Interestingly, artificial transcriptional activators can also be incorporated into therapeutic
plasmids with appropriate promoters to modulate gene expression. In the case of the
gene inhibition approach used to silence the expression of an altered gene with inhibitory
sequences such as miRNA, siRNA or AON delivered by non-viral vectors, the effect is
also transient, which requires repeated administrations [32]. In this case, a permanent
correction of the altered gene can be achieved with the use of CRISPR/Cas9 technology.
Such genome editing tools can be delivered by non-viral vectors complexed to different
genetic constructs such as pDNA, mRNA or RNP complexes [19]. In any case, when time
is a crucial factor, differences in anatomy, physiology, development and biological phe-
nomena between animal labs and human beings should be also considered to extrapolate
experimental results. For instance, it has been estimated that one lived day for rats is
comparable to 30 lived days for humans [65].
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4. Administration Route
The administration route of non-viral vectors affects not only the previously described
gene delivery efficiency and duration of gene expression but also the design of the formu-
lations. To be active at the place of action, non-viral vectors need to overcome different
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biological barriers that strongly depend on both the administration route and the target
organ (Figure 7).




Figure 7. Schematic representation of the main administration routes to face systemic and tissue-specific human diseases 
by non-viral vectors gene therapy approach. 
To overcome the previously described systemic barriers, non-viral vectors can be 
structurally modified. For instance, the addition of positively charged protamine into non-
viral vectors protects the genetic material from enzymatic digestion and, therefore, 
increases the transfection efficiency. This approach has also been successfully used with 
other lipid formulations such as solid lipid nanoparticles [70] or liposomes [71]. Other 
commonly used strategy to increase the stability of non-viral vectors complexes in 
biological fluids and reduce the immune response consists in the addition of 
poly(ethylene glycol) (PEG) chains or other hydrophilic polymers, such as poly(N-vinyl-
2-pyrrolidone) (PVP), into the outer surface of complexes [72]. The neutral PEG chains 
produce a steric barrier against enzymatic degradation and avoid aggregation of non-viral 
vector complexes in systemic circulation [73]. In addition, PEG chains reduce the quantity 
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clinical applications. Another advantage of this administration route includes the use of 
small doses, which in turn, reduces side effects by increasing drug concentration at the 
area of interest. In addition, inhalation can also be used for gene delivery to treat systemic 
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non-viral vectors gene therapy approach.
The main and most studied administration route of non-viral vectors to face dissemi-
nated cancer or infectious diseases is the intravenous route [66]. The idea is to transport
the genetic material to as many cancerous and infected cells as possible. However, effi-
ciency of this interesting and ambitious approach is strongly limited by the enzymatic
degradation that a genetic material can suffer from the point of entry [23]. In addition,
positively charged non-viral vector complexes can interact by non-specific electrostatic
attractions with negatively charged biological compounds such as serum proteins and
blood cells, which limit their final performance [67]. Another concern to be aware of is the
possible instability of such complexes in the extracellular biological medium at physiologi-
cal conditions, where pH value, temperature and ionic stench, among many other factors,
can result in the formation of aggregates along the exposure time [18]. Furthermore, the
systemic administration at high volumes of non-viral vector complexes can trigger the
host immune responses against some of their components, resulting in an inflammatory
response, which can be more pronounced if administrations are repeated [68]. Finally, it is
worth mentioning that endothelial cells of the vascular system constitute a relevant and
effective biological barrier. This barrier can limit the size and number of non-viral vector
complexes that can pass through it, therefore, reducing the transfection efficiency in the
targeted tissues after a systemic administration [69].
To overcome the previously described systemic barriers, non-viral vectors can be
structurally modified. For instance, the addition of positively charged protamine into non-
viral vectors protects the genetic material from enzymatic digestion and, therefore, increases
the transfection efficiency. This approach has also been successfully used with other lipid
formulations such as solid lipid nanoparticles [70] or liposomes [71]. Other commonly
used strategy to increase the stability of non-viral vectors complexes in biological fluids
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and reduce the immune response consists in the addition of poly(ethylene glycol) (PEG)
chains or other hydrophilic polymers, such as poly(N-vinyl-2-pyrrolidone) (PVP), into the
outer surface of complexes [72]. The neutral PEG chains produce a steric barrier against
enzymatic degradation and avoid aggregation of non-viral vector complexes in systemic
circulation [73]. In addition, PEG chains reduce the quantity of cationic lipids required to
deliver a genetic material, which enhances biocompatibility of lipid formulations [74].
Another main route of administration to face devastating diseases that affect the
lungs, such as cancer, cystic fibrosis or asthma, is the pulmonary route. In this case,
intratracheal intubation can be used for gene delivery of pulmonary disease-oriented
treatments. However, the non-invasive nature of the inhalation approach is preferable for
clinical applications. Another advantage of this administration route includes the use of
small doses, which in turn, reduces side effects by increasing drug concentration at the
area of interest. In addition, inhalation can also be used for gene delivery to treat systemic
diseases due to the quick absorption on the alveolar region of lungs [75]. In any case,
the effectiveness of the inhalation process depends mainly on the amount of the genetic
material that will finally reach the targeted region and the deposition pattern, which is
deeply conditioned by the composition of the material to be delivered and by the device
used for inhalation [76]. In this sense, relevant issues such as the characteristics of the
drug delivered, the most adequate pattern for its delivery, the design of the device and its
effectiveness need to be considered in detail to enhance the effectiveness of this appealing
administration route. In the specific case of genetic material-based formulations, the main
difficulty to reach the nucleus of target cells is related to the susceptibility of such molecules
to be degraded by the hydrodynamic shear forces generated during aerosolization process,
which result in a clear decrease of the efficiency compared to in vitro conditions [77].
Some interesting approaches to protect DNA during the aerosolization process consist of
the incorporation of compounds such as bovine serum albumin (BSA), which stabilizes
the supercoiled DNA [78], or the design of efficient aerosol delivery systems for genetic
material, such as nebulizers, dry powder inhalers (DPIs), pressurized metered dose inhalers
(pMDIs) or mechanical metered dose inhalers (mMDIs) [79].
Another relevant issue that hampers the delivery of genetic material to the lung of
affected patients is the presence of specific biological extracellular barriers at this level such
as the alveolar macrophages, the mucus and alveolar fluids, which make the diffusion of
genetic material difficult due to mechanical obstructions and non-specific interactions [80].
In this case, excipients such as mucolytic agents, which improve the mobility of genetic
material, or cell penetrating peptides (CPP), which enhance the cell internalization process,
can be incorporated into non-viral vector formulations to enhance gene delivery efficiency
into the lung [81].
However, there are other relevant organs such as the brain and the eye that, due to
the essential functions that they perform, have developed additional extracellular barriers
over many years of evolution to protect them against foreign agents such as the blood
brain barrier (BBB) and the blood retinal barrier (BRB), respectively, in each organ [82,83].
Consequently, effective gene therapy approaches to treat both inherited and acquired
diseases of the brain and the eye rely, currently, on the in situ administration of genetic
material by invasive routes or in the systemic administration of non-viral vectors decorated
with appropriate ligands to overcome such additional extracellular barriers [23]. In the case
of the brain, most commonly used strategies to cross the BBB include the incorporation
of receptor-mediated uptake of ligands such as insulin, transferrin or lactoferrin, since
endothelial cells of the BBB express high quantity of receptors for such molecules [84]. Other
interesting approaches to cross BBB consist of the addition of specific monoclonal antibodies
that are recognized by receptors of the BBB into the non-viral vector formulations, or the
transient mechanical disruption of the BBB permeability [84]. In the case of the eye, some
studies have demonstrated that submicron-sized formulations based on liposomes or
chitosans, with appropriate ligands such as annexin A5 or transferrin, can target the retina
(which can be damaged in many inherited disease that affect eyesight), after non-invasive
Int. J. Mol. Sci. 2021, 22, 7545 12 of 23
topical application into the conjunctival/scleral tissues [85,86]. Interestingly, non-invasive
approaches have also been described to circumvent BBB. In this case, non-viral vectors
based on 10 kDa polyethylene glycol (PEG)-substituted lysine 30-mers (CK30PEG10k) were
able to deliver EGFP plasmid into the brain after intranasal instillation [87]. All these
findings raise reasonable hope to treat human diseases that affect the eye and the brain by
a safe and effective gene therapy approach based on non-viral vectors administered by
non-invasive routes in the future.
5. Design of Experimental Conditions
To become clinically relevant, non-viral vectors must first meet some critical physic-
ochemical and biophysical parameters that affect the transfection efficiency, such as size,
morphology, superficial charge, thermal stability and rheological properties, to name just
the most relevant ones [88,89]. Normally, this is the first set of experiments that are per-
formed when designing non-viral vector formulations for gene delivery purposes. Even in
this preliminary step, the design of experimental conditions to be evaluated needs to be
considered in detail [48]. For instance, preferably, the nanometric particle size of non-viral
vectors should be reported as hydrodynamic diameter by cumulative analysis [90] rather
than by the area of the predominant peak measured by dynamic light scattering (DLS),
normally in a Zetasizer instrument. However, to use this approximation correctly, and for
comparative purposes, particle size distribution must follow a monomodal distribution,
with a polydispersity index below 0.3. In addition, to be more sensitive to small numbers
of aggregates or dust, such a particle size must preferably be reported as an intensity
correlated function of the scattered light rather than by volume or number of particles
distribution [91]. The particle size of formulations, along with the presence of possible
aggregates, can also be analyzed with appropriate staining reagents such as uranyl acetate
by different microscopic techniques, including transmission electron microscopy (TEM),
cryo-TEM, scan electronic microscopy (SEM) or atomic force microscopy (AFM) [92]. How-
ever, with these approximations, the number of particles analyzed is more limited and not
always provides a pretty correlation with the DLS technique, mainly due to the different
sample manipulation processes between both approaches. Therefore, such microscopy-
based approaches are normally used to provide evidence of the nanoparticles and evaluate
their morphology, since this is another relevant parameter that affects the gene delivery
process [93].
In addition to particle size, the superficial charge of non-viral vectors is another
commonly studied physicochemical parameter that affects the electrostatic interactions
with the genetic material [45]. Superficial charge value can also affect the interaction of
complexes with cell membranes and the stability of colloidal dispersions. In this sense,
high zeta potential values (either positive or negative) prevent aggregation among particles
by electrostatic repulsions [90]. Such a parameter is normally reported as a function of
the zeta potential value, which can also be measured in a Zetasizer instrument by lasser
doppler velocimetry (LDV). In this case, the approximation model used to calculate zeta
potential value is another relevant parameter to be considered, with the Smoluchowski
equation being the most commonly one used [94].
Other parameters that directly affect both particle size and zeta potential values of
non-viral vectors and make the profitably replication of these studies difficult for the sake
of comparison are the pH value and the ionic strength of the measurement medium [95].
Moreover, the electrostatic interaction between non-viral vectors and the genetic material
to obtain the corresponding complexes can be measured at a molecular level through the
heat released when such binding occurs by isothermal titration calorimetry [96] or by
agarose gel electrophoresis assays [48]. When this last technique is used, the protection
capacity of genetic material by non-viral vectors from enzymatic degradation can also be
evaluated. In any case, again, standardized protocols should be implemented to make such
evaluations as unbiased as possible, since many parameters, such as the exposition time to
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the enzyme, the temperature, the composition of the buffer or the potential applied to run
the electrophoresis assay, can impact the final results obtained.
Once non-viral vectors show appropriate physicochemical parameters for gene de-
livery purposes, normally, and before performing any in vivo biological study, the gene
delivery capacity is preliminarily evaluated in in vitro conditions. However, such in vitro
studies that usually also consider the biocompatibility of the formulations, along with the
cellular uptake and posterior intracellular trafficking analysis, are typically validated in ex-
perimental conditions that not always represent the in vivo environment [97]. For instance,
in vitro results are normally obtained in homogenous cell populations that are exposed
to non-viral vectors for long incubation times. Therefore, positive outcomes obtained in
such simplified tests do not always guarantee success in further animal model validation
assays [37]. A more realistic scenario, which better resembles an in vivo environment, is
obtained when immortalized cell lines are substituted by primary culture cells [98]. In
this case, due to the intrinsic characteristics of primary culture cells, transfection efficiency
values normally decrease when compared to immortalized cell lines. Consequently, stud-
ies performed in primarily culture cells or in other difficult-to-transfect cell lines such
as neurons are normally used to report the kind of cells that have been transfected by
immunohistochemistry techniques rather than the transfection efficiency in quantitative
terms [23,44].
Interestingly, more sophisticated in vitro scenarios, that better predict the in vivo
performance of non-viral vectors, can be obtained using, for instance, microfluidic technol-
ogy that resembles extracellular barriers of immune-privileged organs such as the eye or
brain [99] or by application of the recent game changer 3D-bioprinting technology [100].
In any case, and as occurred with the physicochemical studies, the experimental condi-
tions and protocols of biological assays performed in in vitro conditions should also be
standardized for comparative purposes, since there are many variables that can influence
the final results obtained [97] (Figure 8).
For instance, the preparation of complexes plays a pivotal role in the final biological
performance and depends on many factors such as the volumes or quantities used, the
temperature, the order of components addition or the mixing technique, to name just the
most relevant ones. In the case of non-viral vectors based on polymers, a stock aqueous
solution is added to an appropriate volume of a solution, which contains the genetic
material under vigorous vortex mixing for a short period of time at room temperature.
However, normally, in the case of lipid formulations, the electrostatic interaction between
the cationic lipid and the genetic material occurs under gentle mixture with an appropriate
pipette to avoid destabilization of the lipid formulation [33]. In some cases, especially when
large volumes of aqueous solutions are required to obtain the complexes, a hypertonic
medium, based on the incorporation of appropriate isotonic agents such as mannitol, is
added to get a final isotonic medium that will avoid the lysis of cells [37].
Moreover, transfection efficiency is a highly cell-dependent process, which is condi-
tioned by the particular cellular uptake mechanism and the posterior intracellular traf-
ficking pathway used before reaching the nucleus [45]. In this sense, the low division
rate of quiescent cells, such as neurons or primary cells, hampers the entry of exogenous
genetic material into the nucleus, challenging the transfection. On the contrary, phagocytic
cells can be transfected more easily due to their native biological performance. Therefore,
the concept of a unique universal non-viral vector optimized for all clinical applications
is currently abandoned. In fact, the most accepted concept relies on the idea that the
success of non-viral vectors into clinical practice depends on the development of gene
delivery platforms based on multifunctional vectors specifically designed and tailored
for each particular purpose [21]. In any case, and as a preliminary proof of concept, the
first approach to evaluate transfection efficiency of non-viral vectors can be performed,
for instance, in human embryonic kidney (HEK-293) cells, which is a common cell model
easy to be transfected due to the specific biological characteristics of these particular cell
line [37].
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In close relation to the cell type, the transfection experiment conditions can also
influence th results obtained. In this sense, some relevant parameters also need to be
considered. For instance, the confluence ensity of the cells, the presence or absence of
antibiotics d serum in the culture and transfection medium, or the volume and the
quan ty of genetic material that is going to be valuated, which also depend on ar a of
the c ll cultur wells, should be standardized for comparative purposes. Finally, and as
previously mentioned, transfection efficiency can be m asured by differ nt approach s,
although normally reporter gen tic material s used as a proof of concept before moving
to therapeutic genetic material. In ny c se, slight overall readjus ments need t b done
in the non-viral vector/genetic material- sed ratios du to the impact hat both size and
composi ion of the genetic material have on the trans ection effici ncy pro ess [88].
Once positive outcomes have been obtained in in vitro test model , the next step is
the evaluation of the performance into first small and later big a imal models. Moreover,
previously, ethical issues related to the use of animals at preclinical level need to be
addressed. Once again, during this step, the complexes administered into in vivo studies
might suffer slight modifications related to the volumes, doses or composition of the
dilution medium, that depend overall on the administration route to be used [98]. In any
case, success in animal models does not necessary guarantee clinical success into humans,
since animal testing methods cannot fully address translation to human physiology [97].
In such clinical trials, the delicate balance between the potential benefits of the treatment
and the possible associated risks is carefully evaluated under the supervision of a Gene
Therapy Advisory Committee that will also deal with ethical issues [101].
6. Commercialization Process
Although from a scientific point of view, it is possible to deliver genetic material
to specific cells by means of non-viral vector formulations, the regular application into
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medical practice of this gene therapy approach is highly conditioned by other factors that
affect the commercialization process (Figure 9).




Figure 9. Schematic representation of relevant issues to consider across the commercialization way 
of non-viral vectors in gene therapy medical field. 
For instance, the electrostatic interaction between non-viral vector formulations and 
genetic material cargo typically occurs in aqueous medium. However, despite the 
simplicity of this process, batch-to-batch variability can occur due to slight variations 
during the mixture procedure, which is not acceptable in a clinical setting [97]. In addition, 
systems based on aqueous suspensions are highly unstable to allow regular shipping and 
storage for long periods. In this sense, the recent RNA-based lipid vaccines, developed by 
both BioNTech and Moderna to face SARS-CoV-2 virus that causes Covid-19 infection 
represent a clear example of this issue. Interestingly, the development of dry powder 
formulations, where aqueous medium is removed, represents a promising approach to 
circumvent such instability issues. In fact, currently, many companies are working on the 
design and development of stable dry powder RNA-based lipid vaccines against SARS-
CoV-2 virus. Such solid forms can be obtained by freeze drying (lyophilization), spray 
drying or spray congealing techniques [102]. In any case, this technological approach is 
not an easy matter, since both the components of the non-viral vector formulation and the 
genetic material can be degraded during the process. In the case of the lyophilization 
technology, appropriate cryoprotectant agents need to be incorporated into the non-viral 
vector formulation to avoid the formation of ice crystals during the freezing process. In 
addition, relevant parameters of the own technology, such as temperature, vacuum 
pressure and primary and secondary dry periods, need to be optimized to get a 
homogenous dry powder without residual moisture. The spray dryer technology can be 
used as an additional or complementary technique to lyophilization to also obtain a 
product in the form of a dry powder. In this case, the suspensions containing the 
complexes are absorbed and atomized, forming small vesicles on a stream of hot air, 
which causes the rapid solidification of these vesicles and their subsequent separation. As 
in the case of lyophilization, different amounts of excipients, such as mannitol, lactose or 
trehalose, can be added to improve the flow properties, avoiding collapse and 
agglomeration of the vesicles during the process, as well as the reconstruction of the 
vesicles during their rehydration. Likewise, different process parameters require to be 
adjusted, such as the flow rate of the air stream, the gas temperature or the atomization 
Figure 9. Schematic representation of relevant issues to consider across the commercialization way
of non-viral vectors in gene therapy medical field.
r i st , t electrostatic interaction bet ee no -viral vector for ulations and
e etic material cargo typically occurs in aqueous medium. However, despite the simplicity
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mixture proced , which is not ac eptable in a clinical setti g [97]. In additio , systems
ba ed on aqueous suspen ion are highly unstable to allow regular shipping and stor ge
for long periods. In thi sense, the r cent RNA-based lipid vaccines, developed by both
BioNTech and Moderna to face SARS-CoV-2 virus that ca es COVID-19 infection represent
a clear exampl of this issue. Interestingly, the development of dry owder formulations,
where aqueous medium is remove , represents a promising approach to circumvent such
instability issues. In fact, currently, many companies are working on the design and
development of stable dry powder RNA-based lipid vaccines against SARS-CoV-2 virus.
Such solid forms can be obtained by freeze drying (lyophilization), spray drying or spray
congealing techniques [102]. In any case, this technological approach is not an easy matter,
since both the components of the non-viral vector formulation and the genetic material can
be degraded during the process. In the case of the lyophilization technology, appropriate
cryoprotectant agents need to be incorporated into the non-viral vector formulation to
avoid the formation of ice crystals during the freezing process. In addition, relevant
parameters of the own technology, such as temperature, vacuum pressure and primary
and secondary dry periods, need to be optimized to get a homogenous dry powder
without residual moisture. The spray dryer technology can be used as an additional or
complementary technique to lyophilization to also obtain a product in the form of a dry
powder. In this case, the suspensions containing the complexes are absorbed and atomized,
forming small vesicles on a stream of hot air, which causes the rapid solidification of these
vesicles and their subsequent separation. As in the case of lyophilization, different amounts
of excipients, such as mannitol, lactose or trehalose, can be added to improve the flow
properties, avoiding collapse and agglomeration of the vesicles during the process, as
well as the reconstruction of the vesicles during their rehydration. Likewise, different
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process parameters require to be adjusted, such as the flow rate of the air stream, the gas
temperature or the atomization rate of the sample [103]. In the case of the spray congealing
approach, a colloidal dispersion of complexes with appropriate excipients is atomized into
liquid nitrogen with a nozzle [104]. Both the flow rate and the atomizing pressure need to
be optimized to generate frozen droplets. Such frozen droplets are quickly transferred into
a freeze dryer precooled at a shelf temperature. After the evaporation of the nitrogen, freeze
drying is conducted at a vacuum level of 5 Pa to obtain a homogeneous, porous powder,
without residual moisture that will be stored in glass vials for subsequent pulmonary
administration by inhalation.
Another relevant step that hampers the commercialization process of gene delivery of
advanced therapy medical products based on non-viral vectors is the scale-up production
of these drugs, ideally under the Good Manufacturing Practices (GMP) guidelines to avoid
any possible modification in their biological performance [105]. In this sense, it is worth
mentioning the role that the regulatory agencies such as the European Medicines Agency
(EMA) and the Food and Drug Administration (FDA) play to track the manufacturing
process. These agencies specify the requirements needed to get the desired bioequivalence
of formulations and guarantee the safety and efficacy of the new drugs [106]. Normally,
such products are designed and elaborated by small and medium-sized enterprises that
collaborate with academic groups. Although these consortiums are highly engaged in pre-
clinical activities, they have limited manufacturing experience at industrial levels [105]. For
instance, as commented before, non-viral gene therapy products are normally elaborated
in research laboratories when genetic material is mixed with a lipid or polymer aqueous
solution, obtaining small volumes of complexes, around 1 mL or even less [107]. In this
scenario, the standardization of mixing parameters under GMP and the progress towards
clinical application is practically unattainable [108]. In this sense, pilot plants represent an
appealing approach to produce small volumes of this technology-based products, to gain
knowledge about this technology, and later to design full-scale production systems that
can lead in commercial products.
In terms of treatment cost, and contrary to most of the conventional treatment drugs,
gene therapy products focus their interest mainly on rare and specific disorders for a small
population of patients, which raise relevant ethical questions [109]. In fact, the cost of many
gene therapies approved to date is inversely related to the number of patients who could
benefit from them, and in some cases, previously approved drugs for commercialization,
such as Glybera, have been withdrawn from the market due to the low demand of patients
and high cost of treatments [110]. At present, some of the most expensive marketed drugs,
such as Luxturna or Zolgensma, are gene therapy products that use viral vectors to deliver
the genetic material to the place of interest. In this sense, the costs to develop non-viral
gene delivery vectors is clearly marginal if compared with viral counterparts, since mass
production of viral vectors requires the development of expensive scalable and robust
processes that affect, for instance, the studies on cell cultures or the amplification and pu-
rification steps. [111]. However, although being more affordable from an economical point
of view, to reach clinical practice, non-viral vectors require multiple rounds of engineering
and many chemical modifications, including the addition of stabilizing components or
bioactive targeting ligands that increase their complexity and, therefore, the price of the
formulations [105].
In any case, it is worth mentioning that the old idea of a unique conventional treat-
ment for all patients affected by the same pathology is currently out of date. In fact,
next-generation sequencing techniques (NGS) have completely revolutionized the genetic
diagnosis of rare diseases, which enables the development of increasingly personalized ther-
apies based on the genetic code characteristics of each individual [112]. This methodology
allows a fast and accurate analysis of the altered genes at an affordable price. Such genetic
information ensures clinical diagnosis, increases prognosis reliability, enables genetic coun-
seling and opens the door to precision treatments. This is the idea of the new medicine
that allows the design of personalized therapeutic treatments to correct the initial genetic
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defect in each patient and restore affected cell function [113]. A clear example of such
personalized medicine is the recently developed Milasen product, a gene therapy-based
drug created for a single six-year-old patient diagnosed with Batten’s disease, an inherited
neurodegenerative disorder that leads to retinopathy, seizures and impaired mental and
motor skills [114]. In this case, the genome of the patient was sequenced to identify the
specific cause of this disease. Researchers found that neither of the two copies of patient’s
major facilitator superfamily domain containing 8 (MFSD8) gene was functional. In one
of them a pathogenic mutation was found and, in the other one, an insertion of a mobile
genetic element was found, which affected the processing of the mRNA. Without a func-
tional MFSD8 gene, the protein necessary for lysosomes to carry out recycling or processing
activity of molecules in the cell cannot be produced. As a result, proteins or metabolic
substances are accumulated progressively in cells compromising their functionality [114].
From the patient’s genetic information, researchers designed and administered specific
antisense oligonucleotides to face the patient’s disease in a customizable approach. In less
than a year and a half, researchers selected the most effective oligonucleotides, carried
out all the tests on cells obtained from the patient and, after ex vivo evaluation of both
efficiency and toxicity, obtained the pertinent institutional authorization to administer the
drug. Obviously, the widespread extension of this approach to other human diseases by
gene therapy products, based on non-viral vectors, could have a significant impact on the
health parameters of the population and, as a consequence, decrease the economic burden
that represents for the whole of society.
Finally, an ideal scenario to get this appealing approach would also contemplate the
elaboration of personalized non-viral vectors for gene therapy under the umbrella of the
Green Chemistry concept (Figure 10).
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Recent advances in the field of nanotechnology have ade a great revolution in
different biotechnological sectors, including medicine. Consequently, the intake of phar-
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maceutical products has increased considerably among the population over the years.
However, the clinical and industrial application of this progress has been in the spotlight
not only due to the safety risk and possible side effects associated with the use of these
advanced drugs but also due to the negative ecological impact that their waste products
can have on different aspects of the environment, such as water, soil and air. For instance,
the high energy consumption during drug elaboration, along with the use of high amounts
of hazardous organic solvents, has a relevant impact in such issues. In addition, most of
the drugs and metabolites in wastewater reach the wastewater treatment plants (WWTPs),
which are not specifically designed to eliminate these types of compounds. This becomes
the main source of entry into the natural environment, which is of utmost relevance due
to the possible toxicological risks the drugs can produce [116]. Consequently, the field of
Green Nanoscience/Nanotechnology has emerged as a revolutionary strategy to prevent
any associated toxic and negative effect on the environment, through the implementation
of sustainable and ecologically friendly processes across the whole lifecycle from the ex-
traction of nanomaterials and active compounds (Green Extraction) to the application of
the final nanoformulation [115,117]. Some of the Green Nanoscience/Nanotechnology
principles include the election of biomaterials from renewable sources obtained by Green
Extraction methods, the replacement of organic solvents by water or salt solutions, the use
of alternative nontoxic and natural crosslinker, the preferential use of natural tensioactives
or the reduction of operating steps designing straightforward smethods [118–120]. In any
case, notwithstanding the success of Green concepts across inorganic nanoparticles, their
application into organic nanoparticles to design and elaborate non-viral vectors for gene
therapy is still far away to be a regular practice in the research community.
7. Conclusions
The substantial progress that has been achieved during the past years in different
research areas associated with the design of novel gene delivery systems, along with the
gain of knowledge acquired in genomics and structural biology, has raised reasonable
hope to consider the regular application into medical practice of non-viral vectors as gene
delivery systems to face many devastating diseases. Compared to viral vector counterparts,
non-viral vectors show relevant advantages. For instance, they are less limited by the ge-
netic packing capacity, are better tolerated by the host immune system and their production
is easier and cheaper because they do not have the limitations associated with biological
agents. In fact, non-viral vectors are classified as drugs rather than as biological agents by
the regulatory authorities, which enhances the clinical translation. However, the reality is
that non-viral vectors have been poorly translated into clinical practice. Many concerns that
hamper clinical practice of non-viral vectors include low transfection efficiency, short gene
expression effect, difficulties to reach the target cells after in vivo administration, lack of
implementation of standardized protocols for an unbiased evaluation of the performance
of non-viral vectors and issues associated to the commercialization process. Although there
is no universal non-viral vector for all purposes, in our opinion, lipid non-viral vectors are
the closest to reach clinical translation in the gene therapy field. A cutting-edge example is
represented by current lipid nanocarriers that have been successfully developed to face the
COVID-19 disease by an oligo-based therapeutic approach delivering synthetic mRNA as a
nanovaccine. This strategy raises hope to use a gene therapy approach to face diseases with
lipid nanoparticles delivering plasmid DNA in the near future. In any case, the success
of this appealing approach clearly depends on the development of other game-changing
technologies such as big data, tissue engineering or 3D bioprinting to face genetic diseases
from a safe, affordable and multidisciplinary point of view.
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